• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Mark W. Kieran, MD, PhD

Associate Professor, Department of Pediatrics, Harvard Medical School

Associate Professor, Pediatrics, Boston Children's Hospital

Director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute

Contact Info

Mark Kieran
Dana-Farber Cancer Institute
450 Brookline Avenue

Boston, MA, 02215
Mailstop: DA31541F
Phone: 617-632-4907
Fax: 617-632-4897


Mayra Mollinedo
Pediatric Neuro-Oncology
Dana-Farber Cancer Institute
450 Brokline Av
Dana 3154
Boston, MA, 02115
Mailstop: DA31541F
Phone: 617-632-4386
Fax: 617-632-4897

DF/HCC Program Affiliation

Cancer Survivorship
Angiogenesis, Invasion and Metastasis
Outcomes Research

Research Abstract

The pediatric brain tumor program has focused on three areas: clinical care, outcomes/long-term follow-up, and translational/ clinical trials development. My focus has been on the latter area (also see Drs Susan Chi, Dr Peter Manley and Dr Nathan Robison) and is centered on two major aspects: novel biologic agents (ras, PDGFR, SHH, mTOR, ErbB and EGFR small molecule inhibitors) and anti-angiogenic agents (TNP470, thalidomide, AZD2171, celingitide) for children with brain tumors. Using a lab-based pre-clinical model structure, we have initiated a number of clinical trials in these areas through the Children's Oncology Group (COG), Pediatric Brain Tumor Consortium (PBTC), Department of Defense (DOD) NF1 Consortium and the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC).


View All Publications